entertainment -WSS

entertainment

author：comprehensive 2025-10-01 11:34:56 - browse：98161

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Ascension's ugly legal battle over care for poor patients in Texas

WSS

FDA early review: GLP

NEJM study link tiny plastics in blood vessels to heart problems

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

American taxpayers paid $1.8 trillion in health care costs in 2022

Change Healthcare cyberattack prompts Medicare loan program

Merck to acquire Harpoon Therapeutics for $680 million

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Drug repurposing or repositioning? The language matters

The problem with charging patients to message their doctors

Malaria cases in Florida and Texas: Here’s what you need to know

Gene therapy denied for Afghan refugee whose father aided U.S.

Medicare proposal to cover medical devices draws a mixed reaction

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The cancer drug shortage isn’t new — and neither are the solutions

Nonprofit, backed by Microsoft, to certify AI tools in health care

Wikipedia

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Just how do doctors, lawmakers, and the public define abortion?

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

In shift, Texas to cover initial consult for Afghan baby's gene therapy

CDC marks new Covid

Novo Nordisk obesity pill bests Wegovy in early trial

leisure time

entertainment

leisure time

Wikipedia